California Institute for Biomedical Research:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:California Institute for Biomedical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9432
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
California Institute for Biomedical Research (Calibr) is a not for profit organization that offers translational research. The organization discovers and develops therapies for unmet medical needs. It conducts research in the human disease areas of degenerative and age-related diseases, cancer, spinal muscular atrophy, cystic fibrosis, diarheal disease, HIV, and tuberculosis, childhood leukemia, metabolic and cardiovascular diseases, autoimmune and inflammatory diseases among others. It conducts research on a wide range of disease areas to produce paradigm-changing medicines. Calibr is headquartered in La Jolla, California, the US.

California Institute for Biomedical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
California Institute for Biomedical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ark Biosciences Enters into Co-Development Agreement with California Institute for Biomedical Research 10
HitGen Enters into Partnership with Scripps Research Institute and California Institute for Biomedical Research 11
Sirenas to Enter into Agreement with California Institute for Biomedical Research 12
Pfizer Enters into Agreement with California Institute for Biomedical Research 13
Cure SMA Enters into Research Agreement with California Institute for Biomedical Research 14
Licensing Agreements 15
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 15
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 16
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 17
California Institute for Biomedical Research – Key Competitors 18
California Institute for Biomedical Research – Key Employees 19
California Institute for Biomedical Research – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product News 21
03/14/2018: Calibr’s repurposed drug to treat non-viral diarrhea enters into a clinical trial 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Key Facts 2
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
California Institute for Biomedical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
California Institute for Biomedical Research, Deals By Therapy Area, 2012 to YTD 2018 8
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ark Biosciences Enters into Co-Development Agreement with California Institute for Biomedical Research 10
HitGen Enters into Partnership with Scripps Research Institute and California Institute for Biomedical Research 11
Sirenas to Enter into Agreement with California Institute for Biomedical Research 12
Pfizer Enters into Agreement with California Institute for Biomedical Research 13
Cure SMA Enters into Research Agreement with California Institute for Biomedical Research 14
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 15
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 16
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 17
California Institute for Biomedical Research, Key Competitors 18
California Institute for Biomedical Research, Key Employees 19

List of Figures
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
California Institute for Biomedical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[California Institute for Biomedical Research:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Odebrecht SA:企業の戦略的SWOT分析
    Odebrecht SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Saudi Electricity Co:発電所・企業SWOT分析
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Instituto Costarricense de Electricidad:電力:M&Aディール及び事業提携情報
    Summary Instituto Costarricense de Electricidad (ICE) is an autonomous institution of the Government of Costa Rica that provides electricity and telecommunications services. The company generates, transmits and distributes electricity; and constructs, operates, and maintains power plants. It uses cl …
  • Arkle Resources Plc
    Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Invivo Corp-医療機器分野:企業M&A・提携分析
    Summary Invivo Corp (Invivo), a subsidiary of Koninklijke Philips NV is a medical device company that designs, manufactures, and markets patient monitoring systems. The company offers products in various categories such as advanced visualization systems, breast imaging and biopsy solutions, neuro im …
  • Texas Instruments Incorporated (TXN):医療機器:M&Aディール及び事業提携情報
    Summary Texas Instruments Incorporated (TI) designs and manufactures and sells semiconductors to electronics designers and manufacturers the world over. It offers catalog and application-specific standard semiconductor products through its analog chips and embedded processors divisions. Its analog c …
  • CJ Corp (001040):企業の財務・戦略的SWOT分析
    CJ Corp (001040) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Range Resources Ltd (RRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Ltd (Range Resources) is an independent upstream oil and gas company. It explores, develops and produces oil and gas in Georgia, Guatemala and Trinidad. The company works on both onshore and offshore production and its onshore projects are operational through water injection. …
  • Senhwa Biosciences Inc (6492):製薬・医療:M&Aディール及び事業提携情報
    Summary Senhwa Biosciences Inc (Senhwa) is a clinical stage drug development company that develops next generation DNA damage response drugs for the treatment of cancer. The company’s pipeline products include CX-5461 and CX-4945. Its CX-5461, a G4-stabilizing compound, is a Pol I inhibitor that tri …
  • Mellors Catering Services:企業の戦略・SWOT・財務情報
    Mellors Catering Services - Strategy, SWOT and Corporate Finance Report Summary Mellors Catering Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GeoVax Labs Inc (GOVX):製薬・医療:M&Aディール及び事業提携情報
    Summary GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on HIV, Zika virus …
  • Dai Nippon Printing Co Ltd (7912):企業の財務・戦略的SWOT分析
    Dai Nippon Printing Co Ltd (7912) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Dr. Reddy’s Laboratories Ltd (DRREDDY):医療機器:M&Aディール及び事業提携情報
    Summary Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestina …
  • Israel Military Industries Ltd.:企業の戦略・SWOT・財務情報
    Israel Military Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Israel Military Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Endologix Inc (ELGX):企業の財務・戦略的SWOT分析
    Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Insmed Inc (INSM)-医療機器分野:企業M&A・提携分析
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline includes …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NuVasive Inc (NUVA):企業の製品パイプライン分析2018
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • MSC Industrial Direct Co Inc (MSM):企業の財務・戦略的SWOT分析
    MSC Industrial Direct Co Inc (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary BerGenBio ASA (BerGenBio) is a clinical-stage biopharmaceutical company that develops drugs to treat multiple aggressive cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 is an AXL kinase inhibitor which …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆